Codrituzumab, CAS 1365267-33-9

Product Description: Codrituzumab is a monoclonal antibody targeting GPC3 (glypican-3). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth[1][2].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Mika Endo, et al. Abstract 2747: Anti-glypican-3 monoclonal antibody (codrituzumab/GC33/RO5137382) treatment enhances tumor infiltration of PD-L1-positive macrophages, and combination therapy with anti-PD-L1 monoclonal antibody promotes antitumor effects. Cancer Res (2018) 78 (13_Supplement): 2747./[2]Chen G, et al. Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab. Oncotarget. 2018 Jan 2;9(12):10436-10444.

CAS Number: 1365267-33-9

Molecular Weight: N/A

Compound Purity: 95.70

Research Area: Cancer

Solubility: H2O

Target: Others

• Artikelnummer: MEXHY-P99013-10
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99013-10
• Green Labware: Nein
• Verpackungseinheit: 10 mg
• Mengeneinheit: STK